Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep:125:172-177.
doi: 10.1016/j.molimm.2020.07.003. Epub 2020 Jul 21.

Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes

Affiliations

Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes

Jun Wang et al. Mol Immunol. 2020 Sep.

Abstract

Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5'-C-phosphate-G-3' (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression. In this study, we extended the investigation of DHCA epigenetic mechanisms in IL-6 expression in human peripheral blood mononuclear cells (PBMC). Using Lucia Luciferase reporter gene system we identified CpG-rich sequences in which of methylation is influenced by DHCA similar to what observed in response to treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Correlation study showed that DNA methylation at select CpG motifs in the IL-6 promoter correlates with IL-6 gene expression. Our study suggests that DHCA is effective in reducing IL-6 expression in human PBMCs, in part, by regulation of methylation in the IL-6 promoter region.

Keywords: 3(3,4-dihydroxy-phenyl) propionic acid (DHCA); Epigenetics; IL-6; Inflammation; PBMC; Polyphenols.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Figures

Fig. 1
Fig. 1. Role of DHCA on LPS-induced IL-6 expression.
The effect of LPS and DHCA on IL 6 gene expression in PBMCs isolated from six age-matched, male healthy donors. The numbers expressed as percentage of individual controls.
Fig. 2
Fig. 2. Role DHCA on methylation of CpG dinucleotides of IL-6 promoter.
DNA methylation status of the nineteen CpG dinucleotides in healthy human PBMC samples treated with vehicle control, LPS or LPS and DHCA. Data are shown as mean ± SEM, N=6, in triplicate.
Fig. 3
Fig. 3. Human IL-6 promoter region and CpG motifs.
The nineteen CpG dinucleotides in the IL-6 promoter region are highlighted in red. Sequences P-1165/−965. P-697/−394, P-366/−95 enriched in CpG motifs that were cloned into the CpG-free Lucia plasmid for gene expression are highlighted in yellow.
Fig. 4
Fig. 4. Examination of methylation of GpC-enriched motifs in IL-6 promoter region and the role of HDAC.
(A) Lucia CpG-free basic plasmid. (B) Luciferase activity in N2a cells transfected with CpG-free basic plasmids with CpG enriched sequences from IL-6 promoter P-1165/−965, P-697/−394 and P-366/−95. (C-E) Luciferase activity in the presence of vehicle, AZA and DHCA following in cells transfected with control and plasmid containing P-697/−394 and P-366/−95 sequences. Data are shown as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001. n=3–5 per assays in duplicate

Similar articles

Cited by

References

    1. Musselman DL, Evans DL & Nemeroff CB The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 55, 580–592 (1998). - PubMed
    1. Drevets WC Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res 126, 413–431 (2000). - PubMed
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545–1602 (2016). - PMC - PubMed
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018). - PMC - PubMed
    1. Casacalenda N, Perry JC & Looper K Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 159, 1354–1360 (2002). - PubMed

Publication types